Incyte Corp’s recent filing unveils that its EVP, Head of US Oncology Issa Mohamed Khairie unloaded Company’s shares for reported $1.18 million on Jan 07 ’26. In the deal valued at $109.07 per share,10,856 shares were sold. As a result of this transaction, Issa Mohamed Khairie now holds 66,132 shares worth roughly $7.03 million.
Then, Stein Steven H sold 15,634 shares, generating $1,589,978 in total proceeds. Upon selling the shares at $101.70, the EVP & Chief Medical Officer now owns 34,203 shares.
Before that, MOHAMED ISSA bought 10,856 shares. Incyte Corp shares valued at $1,184,051 were divested by the Officer at a price of $109.07 per share.
Mizuho upgraded its Incyte Corp [INCY] rating to an Outperform from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who increased its forecast for the stock in early November from “a Neutral” to “a Buy”. Oppenheimer also remained covering INCY and has decreased its forecast on October 08, 2025 with a “Perform” recommendation from previously “an Outperform” rating. Wells Fargo revised its rating on August 06, 2025. It rated INCY as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of INCY
On Monday, Incyte Corp [NASDAQ:INCY] saw its stock fall -0.51% to $106.33. Over the last five days, the stock has gained 4.46%. Incyte Corp shares have risen nearly 45.40% since the year began. Nevertheless, the stocks have risen 7.65% over the past one year.
How much short interest is there in Incyte Corp?
A steep rise in short interest was recorded in Incyte Corp stocks on 2025-12-31, growing by 1.39 million shares to a total of 10.54 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 9.15 million shares. There was a rise of 13.19%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 01, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $90 price target.
